Savoie et al v. Pennsylvania General Insurance Company et al

Filing 506

ORDER AND REASONS granting in part and denying in part 280 Motion for Partial Summary Judgment as stated herein. Signed by Judge Carl Barbier on 6/10/2019. (cg)

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA
LORITA SAVOIE, ET AL.

CIVIL ACTION
NO. 15-1220

VERSUS
SECTION: J(3)
HUNTINGTON INGALLS, INC., ET
AL.

JUDGE BARBIER
MAG. JUDGE DOUGLAS

ORDER & REASONS
This is an asbestos exposure case. Plaintiffs are the wife and children of Joseph
B. Savoie, Jr. (“Savoie”), who died from mesothelioma. Before the Court is defendant
Avondale’s1 Renewed Motion for Partial Summary Judgment to Establish
the Settlements of Certain Non-Parties. (Rec. Doc. 280), Plaintiffs’ opposition
(Rec. Doc. 344), and Avondale’s reply (Rec. Doc. 478). Avondale seeks to establish that
Savoie entered into eight settlements that released multiple entities from liability for
his mesothelioma, even though those settlements occurred over a decade before he
was diagnosed with that disease. After considering the parties’ arguments, the
summary judgment record, and the applicable law, the Court holds for reasons
explained below that five of the releases included Savoie’s mesothelioma claim, and

As used in this Order & Reasons, “Avondale” refers to Huntington Ingalls Incorporated (f/k/a
Northrop Grumman Shipbuilding, Inc., f/k/a Northrop Grumman Ship Systems, Inc., f/k/a Avondale
Industries, f/k/a Avondale Shipyards, Inc., and f/k/a Avondale Marine Ways, Inc.), Albert L. Bossier,
Jr., J. Melton Garrett, and OneBeacon America Insurance Company and Pennsylvania General
Insurance Company, in their capacities as alleged insurers of James Bull, C. Edwin Hartzman, Hettie
“Dawes” Eaves, Henry “Zac” Carter, John McCue, and Ewing Moore.
1

three did not. Accordingly, the Court grants in part and denies in part Avondale’s
motion.
BACKGROUND
Savoie worked at Avondale Shipyards from approximately 1948 through 1995.
In 1990, Savoie was diagnosed with asbestosis—a respiratory disease that involves
scarring of lung tissue caused by inhalation of asbestos particles. See Rando v. Anco
Insulations Inc., 2008-1163 (La. 5/22/09), 16 So. 3d 1065, 1073 n.4 (defining
asbestosis). In 1991, Savoie and nearly 3,000 other plaintiffs sued multiple
defendants for their asbestos-related injuries in In Re Asbestos Plaintiffs v. Borden,
No. 91-18397, which was filed in Orleans Parish Civil District Court (“the Borden
case”). For Savoie, that litigation resulted in multiple settlements during the 1990s
and the early 2000s.
Years later, Savoie became “one of those tragically unlucky victims whose
exposure to asbestos eventually evolved into mesothelioma.” Hymel v. Eagle, Inc.,
2008-1287 (La. App. 4 Cir. 3/18/09), 7 So. 3d 1249, 1251. Mesothelioma is a type of
cancer that usually begins in the pleura, the membrane that surrounds the lungs and
lines the wall of the chest cavity. Rando, 16 So. 3d at 1072 & n.1. Savoie was
diagnosed with mesothelioma on July 17, 2014. About a month later, he filed the
instant action against Avondale and other defendants, claiming his mesothelioma
was caused by exposure to asbestos at Avondale Shipyards. Savoie passed away on
September 15, 2014. His wife and children were substituted as plaintiffs, and the
petition was amended to assert survival and wrongful death claims.

2

During the course of this litigation, Avondale subpoenaed the Wilson Law
Firm—Savoie’s attorneys during the Borden case2—for copies of Savoie’s settlement
agreements. The subpoena stated that the documents “may have any amounts paid
pursuant to any settlement or compromise deleted.” (Rec. Doc. 280-2 at 2-3). The law
firm responded by producing seventeen release documents with the settlement
amounts redacted. (See Ex. 1 to Avondale’s Mot. for Summ. J., Rec. Doc. 280-2).
Avondale filed the instant motion for partial summary judgment contending
that eight of the seventeen releases discharged not only Savoie’s contemporaneous
asbestosis claim, but all future claims for asbestos-related illnesses, including
mesothelioma, against thirty-one entities. Avondale does not claim to be one of the
releasees, however. Rather, its eventual goal is to use these releases as a basis for
claiming virile-share credits against any judgment that may be rendered against it,
provided it can prove at trial that the releasees are actually at fault for causing
Savoie’s mesothelioma. This is further explained in the margin.3 Plaintiffs raise

The record reflects that Savoie was represented by the Wilson Law Firm and the Murray &
Wilson Law Firm during the Borden case and the resulting settlements. Different counsel represents
Plaintiffs in the case at bar.
3 The parties agree that complete solidary liability under Louisiana law—where multiple
tortfeasors share equally in liability to the plaintiff and any one of them may be compelled to pay the
entire judgment—applies to Plaintiffs’ survival claims (the wrongful death claims were previously
dismissed and are not at issue here, Rec. Doc. 484, but would likely be governed by comparative fault).
Under that regime, if a tortfeasor pays more than his share of a solidary obligation, he could subrogate
to the plaintiff’s rights and seek contribution from other tortfeasors for their respective shares of the
judgment. See Farbe v. Cas. Reciprocal Exch., 2000-0076 (La. 7/6/00), 765 So. 2d 994, 996. However,
when a plaintiff settles with and releases one of several solidary obligors, he deprives the remaining
obligors of the right to contribution against the released obligor. Id. “Accordingly, . . . proof by the
remaining obligors of fault on the part of the released obligor gave rise to a reduction in the plaintiff’s
recovery against the remaining obligors in proportion to the total number of obligors found to be
solidarily liable.” Taylor v. Fid. & Guar. Ins. Co., 630 So. 2d 237, 239 (La. 1993). “Importantly, a
nonsettling tortfeasor is entitled to a reduction in the judgment only if he proves at trial that the
released party was at fault and therefore solidarily liable.” Farbe, 765 So. 2d at 997.
2

3

multiple arguments in opposition, most of which fall into one of two categories: (1)
Avondale has not shown that the release documents constitute enforceable
settlements, and, (2) even if the releases are enforceable in a general sense, they did
not compromise Savoie’s future claim for mesothelioma.
LEGAL STANDARD
Summary judgment is appropriate where the pleadings, depositions, answers
to interrogatories, and admissions on file, together with the affidavits, if any, show
there is no genuine dispute as to any material fact and that the moving party is
entitled to judgment as a matter of law. Little v. Liquid Air Corp., 37 F.3d 1069, 1075
(5th Cir. 1994); Fed. R. Civ. P. 56. The moving party bears the initial burden of
demonstrating to the court that there is an absence of genuine factual issues. Id. Once
the moving party meets that burden, the non-moving party must go beyond the
pleadings and designate facts showing that there is a genuine issue of material fact
in dispute. Id. “A factual dispute is ‘genuine’ where a reasonable jury could return a
verdict for the non-moving party. If the record, taken as a whole, could not lead a
rational trier of fact to find for the non-moving party, then there is no genuine issue
for trial and summary judgment is proper.” Weber v. Roadway Exp., Inc., 199 F.3d
270, 272 (5th Cir. 2000) (citations omitted). The non-moving party’s burden “is not
satisfied with ‘some metaphysical doubt as to the material facts,’ by ‘conclusory
allegations,’ by ‘unsubstantiated assertions,’ or by only a ‘scintilla’ of evidence. [The
courts] resolve factual controversies in favor of the nonmoving party, but only when
there is an actual controversy, that is, when both parties have submitted evidence of

4

contradictory facts. [Courts] do not, however, in the absence of any proof, assume that
the nonmoving party could or would prove the necessary facts.” Little, 37 F.3d at 1075
(emphasis omitted)(citations omitted).
DISCUSSION
The discussion is divided into three parts. First, Louisiana law regarding
release of future claims is reviewed. Second, the Court examines the language of each
release to determine if any included Savoie’s future claim for mesothelioma. This part
also discusses Plaintiffs’ arguments which are specific to a particular release. The
third part addresses Plaintiffs’ arguments that apply to all of the releases.
A.

Law Regarding Release of Future Claims
There is no dispute that Savoie was diagnosed with asbestosis but not

mesothelioma at the time he executed the subject releases. Mesothelioma would not
manifest until thirteen years after the last release was signed. The core issue, then,
is whether Savoie released a future claim for mesothelioma when he executed these
releases.
“A compromise is a contract whereby the parties, through concessions made by
one or more of them, settle a dispute or an uncertainty concerning an obligation or
other legal relationship.” La. Civ. Code art. 3071.4 The burden is on the party
interposing the release to establish the requisites for a valid compromise, including
the parties’ intent to settle their differences in the action. Brown v. Drillers, Inc., 93-

The Court quotes from the current version of the Civil Code, although older versions of those
articles apply to Savoie’s survival claims. The parties agree, however, that the intervening revisions
did not change the substantive law.
4

5

1019 (La. 1/14/94), 630 So. 2d 741, 754; but cf. Hymel, infra. “A compromise settles
only those differences that the parties clearly intended to settle, including the
necessary consequences of what they express.” La. Civ. Code art. 3076. While
Louisiana law does not prohibit parties from settling potential future claims that may
arise from a past breach of duty, “releases of future actions are narrowly construed
to assure that the parties fully understand the rights released and the resulting
consequences.” Brown, 630 So. 2d at 754. “[I]f the release instrument leaves any
doubt as to whether a particular future action is covered by the compromise, it should
be construed not to cover such future action.” Id.
Brown explained that “the meaning and intent of the parties to a written
instrument, including a compromise, is ordinarily determined from the four corners
of the instrument, and extrinsic (parol) evidence is inadmissible either to explain or
to contradict the terms of the instrument.” Id. at 748. However, “a general release
will not necessarily bar recovery for those aspects of a claim not intended by the
parties to be covered by the release.” Id. at 749. When a party produces
“substantiating evidence of mistaken intent,” a court may look beyond the four
corners of the instrument to ascertain intent. Id. Absent such evidence, however,
courts “have not hesitated to confine their analysis to the four corners of the
instrument.” Id. at 750.
Two post-Brown decisions by Louisiana intermediate appellate courts provide
useful guideposts. In Breaux v. Mine Safety Appliances Co., 98-133 (La. App. 5 Cir.
8/25/98), 717 So. 2d 1255, the plaintiff sued for asbestosis in 1982. Around that time,

6

the plaintiff’s doctors informed him that he did not have asbestosis. In 1983, the
plaintiff executed a release in favor of the defendant in exchange for $500. The
document stated that the plaintiff released the defendant “from any and all claims . .
. or disabilities of any nature whatsoever, including but not restricted to asbestosis,
silicosis and/or pneumonoconiosis, past, present or future, and any and all other
claims, past, present or future arising out of . . . occupational diseases contracted
while employed at or by [defendant].” Id. at 1257. Thirteen years later, the plaintiff
developed mesothelioma and sued the same defendant again. The Louisiana Fifth
Circuit held that the previous release did not bar the plaintiff’s current mesothelioma
claim, explaining:
Although the agreement refers to “disabilities of any nature”, “past,
present or future,” “arising out of or in any manner whatsoever
connected with or resulting from, either directly or indirectly, injury
sustained or occupational diseases contracted while employed at or by
[the defendant],” it is not logical to expect that plaintiff intended to
release defendant for the future manifestation of this type of cancer for
$500. This is a terrible disease. If the agreement intended to include
mesothelioma, defendant would surely have included it in the listed
diseases. As plaintiff argues, this settlement was a nuisance settlement.
Thus, we find that the language of the agreement does not include the
contraction of this type of cancer which would not manifest for many
years, nor did plaintiff intend to include it in the settlement. Plaintiff
signed the agreement expressly because he did not have any of the
asbestos related diseases at that time.
Id.
The Louisiana Fourth Circuit reached the opposite result in Hymel v. Eagle,
Inc., 2008-1287 (La. App. 4 Cir. 3/18/09), 7 So. 3d 1249. In that case, the plaintiff was
diagnosed with asbestosis in 1993, sued the same year, and then executed a release
in 1998 in exchange for $15,000. The release stated:

7

It is further understood and agreed that the aforementioned provisions
are intended to release and forever discharge the released parties from
any and all liability on account of or in any way growing out of
occupational diseases or conditions attributable to exposure to asbestos
. . . including . . . any future or consequential condition or injury,
including but not limited to death, mesothelioma, cancer, shortness of
breath, fear of cancer or increased risk of cancer . . . .
Id. at 1252 (emphasis added in Hymel). Years later, the plaintiff developed
mesothelioma and sued the same defendant again. The court held that the prior
release “clearly and unambiguously compromised any prospective claims that the
plaintiff might have for mesothelioma or cancer.” Id. at 1258. The court distinguished
the facts before it from those considered in Breaux, noting:
(1) the settlement specifically covered both mesothelioma and cancer by
name, (2) the plaintiff had an asbestos related disease at the time he
signed the settlement (asbestosis); (3) it was for a sum thirty time[s]
greater than the settlement in Breaux and, therefore, cannot be
characterized as a “nuisance settlement”; and (4) there is no indication
in Breaux that the plaintiff had the potential to recover additional sums
from other defendants as there is in the instant case.
Id. at 1254 (emphasis in original). Hymel further explained:
Where a settlement and release refer expressly to the claim
sought to be released by the party seeking to enforce the settlement, that
alone is sufficient to shift the burden to the party seeking to oppose the
enforcement of the settlement and release to prove that there was no
meeting of the minds or that there was fraud or ill practices. It is not
sufficient to raise the issue to merely make the self-serving allegation
that there was no meeting of the minds. A party represented by counsel
may not defeat a written settlement and release that is unambiguous on
its face by merely alleging that he did not understand it. Otherwise, no
settlement would be enforceable without more litigation which defeats
the whole public policy favoring settlements. Signatures on documents
are not mere ornaments. . . . There is little incentive to settle if a party
to the settlement agreement may later seek to void it based merely on
his self-serving statements, without more, and in the absence of any
evidence of fraud or ill practices, that he misunderstood what he signed
or that he did not intend to sign what he signed.

8

Id. at 1257-58 (citations omitted).
With this background in mind, the Court turns to the language in the eight
releases.
B.

The Eight Releases
1.

Champion Release

In the Champion Release, dated March 20, 1996, Savoie and his wife released:
Champion International Corporation, and its predecessor U.S. Plywood
Corporation . . . from any and all claims . . . which we now may have or
in the future may have against Champion . . . in any manner arising
out of or in any way connected with . . . the alleged exposure of the
Injured Person to various asbestos-containing materials . . . as well as
any and all consequences thereof, whether heretofore or hereafter
accrued or whether known or unknown to the Claimants . . . .
...
We understand that the Injured Person now may be suffering from or,
in the future, may suffer from asbestos-related diseases or injuries
(such as cancer or mesothelioma) . . . which diseases and/or injuries
may not have manifested themselves at the present time. It is our
intention and agreement that any claims against Champion, of any kind
or character whatsoever, which we might have for, and/or arising out of
or related to, any such asbestos-related diseases and injuries and/or
death, are the subject of this Release and are hereby released.
(Rec. Doc. 280-2 at 38-39)(emphasis added).
The Court finds that the Champion Release, like the release in Hymel, supra,
clearly and unambiguously released Savoie’s future claim for mesothelioma (i.e., the
survival claims asserted in this action). Not only does it generally release “all claims
. . . which we . . . in the future may have against Champion . . . whether heretofore or
hereafter accrued or whether known or unknown to the Claimants,” it specifically

9

releases future claims for “cancer or mesothelioma.” While the burden was initially
on Avondale to show that a future claim for mesothelioma was within the scope of
this release, see Brown, 630 So. 2d at 747, “[w]here a settlement and release refer
expressly to the claim sought to be released by the party seeking to enforce the
settlement, that alone is sufficient to shift the burden to the party seeking to oppose
the enforcement of the settlement and release to prove that there was no meeting of
the minds or that there was fraud or ill practices,” Hymel, 7 So. 3d at 1257. Plaintiffs
have “cited no cases in which a court has invalidated a settlement where the future
claim arose out of the original alleged dereliction of duty and was specifically
mentioned in the release and the plaintiff was represented by counsel.” Id. at 1253.
Plaintiffs raise no arguments specific to the Champion Release. However,
Plaintiffs have raised several arguments which are applicable to all of the releases,
including the Champion Release. Such arguments are discussed below in Part C. For
now, however, the Court concludes that the language used in the Champion Release
was sufficient to release Savoie’s future mesothelioma claim.
2.

Met Life Release

The relevant language in the Met Life Release, dated September 5, 1997, is
virtually identical to the language in the Champion Release, including the explicit
reference to “cancer or mesothelioma.” (See Rec. Doc. 280-2 at 11, 13). For the same
reasons discussed with the Champion Release, the Court finds that the scope of the
Met Life Release included Savoie’s future claim for mesothelioma.

10

Plaintiffs raise one argument that is specific to the Met Life Release. Plaintiffs
point out that Metropolitan Life Insurance Company, the released entity, is an
insurance company. Plaintiffs contend that under the law of solidary liability an
insurer is not assigned a virile share separate from that of its insured. Plaintiffs
assert, “To establish Metropolitan Life Insurance Company as a ‘settled entity’ only
begs the question of what entities [Metropolitan Life] was insuring, and whether
there were other insurers.” (Pls. Opp’n at 14-15, Rec. Doc. 344). Be that as it may, it
does not stop the Court from finding that the scope of the Met Life Release included
Savoie’s mesothelioma claim against Metropolitan Life Insurance Company. The
issue here is not whether Avondale will receive a virile-share credit for this or any
other release. Avondale will have to prove certain elements at trial before it obtains
a credit for the Met Life Release, see note 3 and accompanying text, supra, and this
would seem to include establishing the identity and liability of Metropolitan Life’s
insured.
3.

Amchem Release5

In the Amchem Release, dated May 24, 2000, Savoie and his wife released:
Amchem Products, Inc. [and multiple other entities listed in the
margin6] from any and all rights, claims, demands . . . of whatever kind
or nature which we now have, or may have in the future for personal
Plaintiffs refer to this document as the CCR Release, short for Center for Claims Resolution.
The Amchem Release identifies the following as “Releasees”: “Amchem Products, Inc.; Gasket
Holdings, Inc. (F/K/A Flexitallic, Inc.); GAF Corporation; Ferodo America, Inc.; Armstrong World
Industries, Inc.; The Asbestos Claims Management Corporation (formerly known as National Gypsum
Company) and the NGC Asbestos Disease and Property Damage Settlement Trust; CertainTeed
Corporation; C.E. Thurston and Sons, Inc.; Dana Corporation; I.U. North America, Inc.; Rhone Poulenc
(Tendered To Amc) Maremont Corporation; National Services Industries Inc.; NOSROC Corp.; Pfizer
Inc.; Quigley Company, Inc.; Shook & Fletcher Insulation Co.; T & N, plc; Union Carbide Corporation
(f/k/a Union Carbide Chemicals & Plastics Company, Inc.); and United States Gypsum Company.”
(Rec. Doc. 280-2 at 27).
5
6

11

injuries, disability . . . mesothelioma, cancer, fear of cancer, or any
other asbestos-related disease or condition, whether diagnosed or
undiagnosed . . . which may be related to, result from or arise out of
JOSEPH B. SAVOIE’s inhalation or ingestion of, contact with, or
exposure to, or use of . . . asbestos-containing products which may have
at any time been manufactured . . . by any of the Releasees . . . .
(Rec. Doc. 280-2 at 27) (emphasis added).
As with the Champion Release, the Court finds that the scope of the Amchem
Release included Savoie’s future claim for mesothelioma.
Plaintiffs raise a few issues that are unique to the Amchem Release. First, the
parties disagree over how many entities are purportedly released by the Amchem
Agreement—Plaintiffs count nineteen while Avondale counts twenty-one. This issue
pertains to how many virile-share credits Avondale may claim with respect to the
Amchem Release, which the Court does not consider here. Just as Avondale must
prove at trial that a particular releasee is liable for Savoie’s mesothelioma in order to
receive a virile share credit for that releasee, Plaintiffs may present evidence that
multiple releasees should be counted as a single virile share because, for example,
they share a common root. See, e.g., Cole v. Celotex Corp., 599 So. 2d 1058, 1073-74.
Plaintiffs also argue that the Amchem Release is controlled by what they refer
to as the “Master Agreement,” which they claim “makes clear that with regard to
those claims which were non-malignant claims at the time of the settlement, there
was no intent to release future mesothelioma claims.” (Rec. Doc. 344 at 9). Plaintiffs
cite to a document entitled “Future Plaintiff Agreement,” which is attached to their
brief. (Rec. Doc. 344-8 at 30).7 The Future Plaintiff Agreement states that it applies

7

There is no “Master Agreement” attached to Plaintiffs’ brief.
12

to “the claims of all asbestos personal injury plaintiffs/claimants who, after the date
of this Agreement, retain [Alwyn H. Luckey, Esquire and Wm. Roberts Wilson, Jr.
(individually and as agents for their law firms, Law Offices of Alwyn H. Luckey and
Wm. Roberts Wilson, Jr., P.A.)] . . . to file claims in Louisiana alleging personal injury
or death arising from the exposure of such plaintiffs/claimants or their decedents [sic]
to asbestos-containing materials . . .” (Id. at 31) (emphasis added). There is no date
on the Future Plaintiff Agreement, but its content suggests it was written years after
Savoie retained Wilson to represent him in the Borden case. Therefore, the Future
Plaintiff Agreement does not appear to apply to Savoie.
Even assuming the Future Plaintiff Agreement did apply to Savoie, that
document does not support Plaintiffs’ position. Plaintiffs quote the following passage
as proof for their contention that Savoie did not release his future claim for
mesothelioma:
Appendix 6 to the Agreement is an agreed-to release form which will be
executed by all Plaintiffs alleging a Non-Malignant I condition. That
Release shall release all claims with the exception of claims that meet
the medical documentation requirements in the medical documentation
requirements in the Mesothelioma, Lung Cancer, or Other Cancer
disease categories . . . .
(Id. at 52) (emphasis added). Appendix 6 has not been provided to the Court.
However, the fact that the Amchem Release expressly includes, rather than excepts,
future claims for mesothelioma and cancer strongly suggests that the “Appendix 6”
referred to in the Future Plaintiff Agreement is not the release that Savoie signed
and therefore has no bearing on this case.

13

Finally, Plaintiffs raise an argument respecting one of the releasees identified
in the Amchem Release, Shook & Fletcher Insulation Company (“Shook & Fletcher”).
Plaintiffs point out that there is another settlement document in the record, “the
Shook & Fletcher Release” dated May 13, 2002 (i.e., after the Amchem Release),
where Savoie and his wife expressly reserved any future claims against Shook &
Fletcher for “cancer [or] mesothelioma . . . not diagnosed as of the date hereof.” (Rec.
Doc. 280-2 at 22-23). Thus, there are two documents in the record that purport to
release Shook & Fletcher: one that concerns multiple releasees and explicitly releases
future mesothelioma claims, and the one that concerns only Shook & Fletcher and
explicitly reserves future mesothelioma claims. The Court finds that the Shook &
Fletcher Release is “substantiating evidence of mistaken intent” sufficient to
overcome the unequivocal language in the Amchem Release, but only insofar as the
Amchem Release purports to release Shook & Fletcher.
In conclusion, the Court holds that the scope of the Amchem Release included
Savoie’s future mesothelioma claim, except with respect to Shook & Fletcher.
4.

Chesterton Release

In the Chesterton Release, dated April 11, 1997, Savoie released:
A.W. Chesterton Company . . . from any and all claims . . . whether
presently existing or arising in the future, with respect to any and all
diseases or injuries, presently existing or hereafter arising
(including any asbestos related cancer), that were caused by or
could be associated with exposure to Chesterton’s asbestos-containing
products and any wrongful death actions . . . and/or any survival actions
....

14

(Rec. Doc. 280-2 at 5) (emphasis added). Unlike the release in Hymel and the other
releases discussed above, the Chesterton Release does not specifically mention
mesothelioma. Despite this omission, the Court finds that the Chesterton Release did
release Savoie’s future mesothelioma claim.
The central concern in Brown was “whether the language employed in the
release instrument reflects that the parties clearly comprehended, in light of
surrounding circumstances, a release of future . . . claims.” Brown, 630 So. 2d at 752;
see also id. at 753 (“[R]eleases of future actions are narrowly construed to assure that
the parties fully understand the rights released and the resulting consequences.”); id.
at 744 (“[W]e add a requirement that the release instrument unequivocally reflect,
while not necessarily by express reference, that the parties clearly contemplated a
compromise of future wrongful death claims.”). Although it does not specifically
mention mesothelioma, the Chesterton Release does release all future claims
“including any asbestos related cancer.” Of course, mesothelioma is an “asbestos
related cancer.” See Rando v. Anco Insulations Inc., 2008-1163 (La. 5/22/09), 16 So.
3d 1065, 1072 & n.1. Furthermore, while the average person would understand the
meaning of the word “cancer,” it is questionable whether he or she would comprehend
a term like “mesothelioma.” Thus, the fact that the Chesterton Release does not
mention mesothelioma does not distinguish it in a meaningful way from the release
in Hymel or the Champion, Met Life, and Amchem Releases. The Court finds that the
language employed in the Chesterton Release reflects that the parties clearly

15

comprehended, in light of surrounding circumstances, that Savoie was releasing his
future claim for mesothelioma.
5.

A. P. Green Release

In the A.P. Green Release, dated January 24, 2001, Savoie released:
A.P. Green Industries, Inc. . . . from any and all rights, claims, . . . [he]
now [has] or may have in the future for personal injuries (physical or
psychological), disability, . . . cancer, fear of cancer, or any other disease
or condition . . . which may be related to . . . Worker’s inhalation or
ingestion of asbestos fibers . . . [or] exposure to . . . other asbestos
containing products . . . . Releasors state that they understand that
medicine is not an exact science and that Releasors may now have or
may contract in the future an asbestos . . . related condition
which has not been diagnosed. Releasors state that in consideration
of the above payment, they accept the risks of any such current and
future conditions, and that it is their intentions to fully release the
Parties Released Herein . . . with regard to same.
...
This [Release] and the consideration paid herewith is to extinguish all
claims for injuries and wrongful death from Releasors’ exposure to
asbestos . . . including past, present, and future injuries, wrongful
death, as well as all personal and survival rights, and is intended and
accepted as full and final accord and satisfaction should Worker later
expire as a result of asbestos . . . related disease.
(Rec. Doc. 280-2 at 24) (emphasis added).
The A.P. Green Release releases all future claims and explicitly mentions
“cancer,” although it does not mention “mesothelioma.” The Court finds for essentially
the reasons stated above with the Chesterton Release that the scope of the A.P. Green
Release included Savoie’s future claim for mesothelioma.
6.

B & W Release

In the B & W Release, dated December 15, 1990, Savoie released:

16

Babcock and Wilcox Company . . . from any and all demands, suits, . . .
injuries, . . . [and] claims . . . of every type, kind and character
whatsoever, that the undersigned . . . may now or may hereafter have
arising out of or in any way related to the exposure of the undersigned .
. . to asbestos-containing products . . . .
(Rec. Doc. 280-2 at 42).8
Unlike the release in Hymel and the other releases addressed above, the B &
W Release does not specifically mention a future claim for mesothelioma or cancer.
Nor does the B & W Release include language where Savoie acknowledges that he
may later develop an asbestos-related disease and that such is included in the release,
as occurs in the Champion Release, the Met Life Release, and the A.P. Green Release.
On the other hand, the B & W Release does not specifically reserve a future claim for
mesothelioma or cancer, as was done in the Shook & Fletcher Release.
The language in the B & W Release is similar to the release considered by the
Louisiana Fifth Circuit in Breaux, which was held not to include the plaintiff’s future
mesothelioma claim.9 The outcome in Breaux was also influenced by the low
settlement amount, $500. Here the amount is redacted, but the Court will assume it

The record contains another release, dated May 20, 1992, that is similar, but not identical, to the
B & W Release. (Rec. Doc. 280-2 at 18-19). Because both sides discuss only the 1990 B & W Release,
the Court does the same.
9 The release in Breaux is reproduced for the reader’s convenience:
8

[Plaintiff releases defendant] . . . from any and all claims, demands, damages,
actions or suits including any and all claims for medical, hospital or other
expenses or personal injuries or disabilities of any nature whatsoever,
including but not restricted to, asbestosis, silicosis and/or pneumonoconiosis,
past, present or future, and any and all other claims, past, present or future
arising out of or in any manner whatsoever connected with or resulting from,
either directly or indirectly, injury sustained or occupational diseases
contracted while employed at or by [defendant] . . . .
Brown,717 So. 2d at 1257.
17

was a similarly low number.10 While not all of the facts align (the plaintiff in Breaux
did not have an asbestos-related disease at the time he signed the release, whereas
Savoie did), the Court finds the B & W Release did not release Savoie’s future claim
for mesothelioma for essentially the reasons expressed in Breaux. The Court denies
Avondale’s motion for partial summary judgment with respect to the B & W Release.
7.

Combustion Engineering Release

The Combustion Engineering Release, dated February 26, 1999, is almost
entirely illegible. For this reason, the Court denies Avondale’s motion with respect to
the Combustion Engineering Release.
8.

Garlock Release

The language in the Garlock Release, dated May 17, 1996, is somewhat unique
compared to the other seven releases. Savoie released:
Garlock Inc., The Anchor Packing Company, Colt Industries Inc. and
Coltec Industries, Inc [the “Garlock and Anchor Entities”] . . . from any
and all causes of action, . . . claims and demands of whatever kind or
nature . . . which Plaintiff now has or has ever had against [the
Garlock and Anchor Entities] for, upon or by reason or any of the facts
alleged by Plaintiff in the [Borden] Litigation, whether in contract or in
tort, property damages and any other damages, which have accrued or
may ever accrue to Plaintiff or his heirs, executors, . . . successors, or
assigns regarding Decedent’s exposure to asbestos-containing products
distributed by Garlock and Anchor.
...
Plaintiff declares that in executing this Release he is releasing the
Garlock and Anchor Entities from all claims relating to the Plaintiff’s
alleged asbestos-related disease including but not limited to claims for
The Court makes this assumption because Avondale carries the initial burden as the mover on
summary judgment and as the one interposing the release. As discussed in Part C, infra, the Court
does not make the same assumption for the releases that specifically include mesothelioma and/or
cancer, because the express language in those releases shifted the burden to Plaintiffs.
10

18

his pleural disease, asbestosis, any type of asbestos-related cancer
and/or mesothelioma.
(Rec. Doc. 280-2 at 15, 16) (emphasis added). At first blush, the Garlock Release
resembles the Champion, Met Life, and Amchem Releases in that it specifically
mentions “cancer and/or mesothelioma.” Notwithstanding this language, it is not
clear that Savoie released any future claims in the Garlock Release.
In the first paragraph, the emphasized phrase “now has or has ever had”
appears to limit the release to present and past diseases. Avondale contends that the
second emphasized phrase, “or may ever accrue,” modifies “any and all causes of
action,” bringing future diseases within the scope of the release. However, given the
phrase’s proximity to “damages” and relative distance from “any and all causes of
action,” one could reasonably interpret “or may ever accrue” as modifying only
“damages,” such that Savoie was releasing any future damages that may later accrue
as a result of the disease he suffered at that time (e.g., future medical bills Savoie
might incur in treating his asbestosis). Notably, interpreting “or may ever accrue” in
this manner harmonizes that phrase with “now has or has ever had,” whereas
Avondale’s interpretation places these phrases in tension.
Turning to the second paragraph, it is also phrased in the present and past
tense: “Plaintiff . . . is releasing . . . all claims relating to the Plaintiff’s alleged
asbestos-related disease . . . .” The only asbestos-related disease that Savoie alleged
at that time was asbestosis. While the release lists other diseases, including
mesothelioma, this is not surprising given that there were numerous plaintiffs in the
Borden litigation alleging a variety of asbestos-related diseases.

19

Releases of future actions are narrowly construed. Brown, 630 So. 2d at 753.
“As a result, if the release leaves any doubt as to whether a particular future action
is covered by the compromise, it should be construed not to cover such future action.”
Id. At a minimum, the Garlock Release leaves doubt as to whether Savoie released a
future claim for mesothelioma. Accordingly, the Court denies Avondale’s motion for
partial summary judgment with respect to the Garlock Release.
C.

Plaintiffs’ Arguments Against All Releases
As explained above, five of the eight releases included Savoie’s future claim for

mesothelioma: the Champion Release, Met Life Release, Amchem Release,
Chesterton Release, and A.P Green Release. Plaintiffs raised some arguments
specific to those releases, which were already discussed. Plaintiffs also raise seven
arguments that apply to all of the releases. The Court considers those arguments
here.
First, Plaintiffs assert that the releases are inadmissible because they have
not been authenticated. Federal Rule of Evidence 901 generally requires the
proponent (here, Avondale) to “produce evidence sufficient to support a finding that
the items is what the proponent claims it is.” Fed. R. Evid. 901(a). Rule 901 also
provides examples of how this requirement may be satisfied, including “[t]estimony
that an item is what it is claimed to be.” Fed. R. Evid. 901(b)(1). Avondale produced
an affidavit from Bradley Hiatt, an attorney with the firm that represented Savoie in
the Borden case, who certified that the releases were true and correct copies of
documents produced in response to Avondale’s subpoena requesting “[a]ny and all

20

documents concerning or reflecting settlements, compromises and agreements to
settle or compromise any claims asserted by Joseph B. Savoie, Jr. . . . in connection
with Mr. Savoie’s alleged asbestos related illness or any occupational diseases . . . .”
(Rec. Doc. 280-2 at 1-2). Mr. Hiatt further testified:
We searched through the [firm’s] records as they are kept in the normal
course of business over a stretch of three days. After that exhaustive
search, these are the documents that were found that were kept in the
regular course of business. These are the documents specifically found
in Mr. Joseph Savoie’s file.
(Rec. Doc. 478-2 at 9, Depo. Tr. p. 35); (See also Rec. Doc. 478-2 at 3, Depo. Tr. p. 1112). Savoie’s wife testified during her deposition that the signatures on the release
documents belong to her husband and herself. (See, e.g., Rec. Doc.478-1 at 28). The
documents have been authenticated.
Second, Plaintiffs point out that all of the documents submitted by Avondale
pre-date Savoie’s diagnosis of mesothelioma by many years. Plaintiffs further urge
that a cause of action for mesothelioma is separate from a cause of action for
asbestosis. Be that as it may, the Louisiana Supreme Court has made clear that a
party may release a future claim. See Brown, 630 So. 2d at 744.
Third, Plaintiffs argue that the releases were not signed by any of Savoie’s
children. While this might be relevant to the children’s wrongful death claims, the
Court has dismissed those claims with respect to Avondale (See Rec. Doc. 484); only
survival claims are at issue here.11 Unlike a wrongful death action, which
compensates the decedent’s beneficiaries for their injuries that result from the

Furthermore, the parties appear to agree that comparative fault, not solidary liability, would
apply to the wrongful death claim.
11

21

victim’s death, a survival action is based upon the victim’s right to recover for his own
injuries being transferred to the beneficiary upon the victim’s death. Walls v. Am.
Optical Corp., 98-0455 (La. 9/8/99), 740 So. 2d 1262, 1273-74. If Savoie released his
mesothelioma claim, that claim could not transfer to his children upon Savoie’s death.
Therefore, the fact that his children did not sign the release is irrelevant to the
survival claims.
Fourth, Plaintiffs argue that Avondale has produced no evidence that Savoie
was actually compensated for signing any of the releases, and therefore no valid
settlement or compromise exists. Plaintiffs indirectly quote12 Bielkiewicz v. Rudisill,
201 So. 2d 136, 141 (La. 3d Cir. 1967), which stated, “A unilateral ‘release’, whereby
without any shown consideration one party recieves nothing in exchange for the
release of his claim, simply does not meet the legal requirements of a valid
compromise which is res judicata between the parties.” However, the release in
Bielkiewicz did not state on its face, nor was it proved by other evidence, that any
consideration was exchanged for the release. Id. at 140. This was key to the court’s
decision that no compromise existed, implying that if the release had stated that
consideration was exchanged, the compromise would have been upheld. See id. at 141
(“We therefore conclude that the exception of res judicata must be overruled, because
the unilateral ‘release’ executed herein by each plaintiff without shown or proved
consideration does not constitute a binding bilateral compromise which may be the
basis of res judicata.” (emphasis added)). Here, all of the releases except one state

Plaintiffs quote from Williams v. Winn Dixie, 447 So. 2d 8, 10 (La. 4th Cir. 1984), but Williams
was quoting Bielkiewicz.
12

22

that at the time Savoie signed, he did so “for sums paid,” for “cash in hand paid,” for
amounts “the receipt . . . of which are hereby acknowledged,” or for amounts “this day
received.”13 Under Bielkiewicz’s reasoning, then, the compromises are enforceable.
Furthermore, while Avondale bears the initial burden of proving the requisites
for a valid compromise, see Brown, 630 So. 2d at 747, Savoie’s acknowledgment in the
release that compensation was paid shifted the burden to the Plaintiffs to show that
there is at least a genuine dispute as to whether compensation was paid. Cf. Hymel,
7 So. 3d 1256-57 (when a settlement expressly releases the claim at issue, the burden
shifts to the opposing party to show the parties did not intent to settle that claim).
Plaintiffs fail to meet this burden. Plaintiffs cite to the deposition of Lawrence
Fitzpatrick, an employee of the Center for Claims Resolution, which negotiated the
Amchem Release. Mr. Fitzpatrick testified that seven of the nineteen entities listed
in the Amchem Release entered bankruptcy around September 2002, which caused a
settlement with Clemcy Legendre to be mostly unfunded. (Rec. Doc. 344-8 at 18-20,
Depo. Tr. pp. 67-76). But this testimony concerns events that took place two years
after Savoie signed the Amchem Release, and Fitzpatrick never mentions Savoie or
any of his settlements. Plaintiffs produce no evidence showing that Savoie did not
receive consideration for signing any of the releases. Because it was Plaintiffs’ burden
to do so, their fourth argument fails.
Fifth, Plaintiffs argue that none of the releases were signed by any of the
entities purportedly released by those instruments. As a general rule, Louisiana law

The Garlock Release is the outlier. As discussed above, however, the scope of that release did
not include Savoie’s future mesothelioma claim. Thus, the Garlock Release is no longer at issue.
13

23

requires that settlement agreements be reduced to writing and signed by both
parties. See Felder v. Georgia Pac. Co., 405 So. 2d 521, 523 (La. 1981). There are
exceptions to this rule, however. See, e.g., id. at 524 (signatures need not appear on
the same document). In Brown, the Louisiana Supreme Court stated that “a release
of a claim executed in exchange for consideration received is, in effect, a compromise
which can form the basis for a plea of res judicata.” 630 So. 2d at 747 n.5; accord
Bielkiewicz, 201 So. 2d at 140-141 (indicating that a release signed only by the
plaintiff would have been enforceable had it stated on its face or there was evidence
showing that consideration was exchanged). As just explained, all of the releases
except one state on their face that Savoie received consideration in exchange for the
release, and Plaintiffs have produced no evidence to contradict this. Accordingly,
Plaintiff’s fifth argument is rejected.
Sixth, Plaintiffs complain about the fact that the settlement amounts in the
releases are redacted. Plaintiffs contend the amount is critical, as the court in Breaux
viewed a $500 settlement as a nuisance settlement that did not release a future
mesothelioma claim, while Hymel concluded a $15,000 settlement did release a future
mesothelioma claim. Plaintiffs give too much weight this distinction. The primary
difference between Breaux and Hymel is the specificity of the release language, not
the settlement amount. The very first point Hymel makes when discussing Breaux is
that the release in Breaux “does not use the words ‘cancer’ or mesothelioma,’” whereas
the release before it “specifically covered both mesothelioma and cancer by name.”
Hymel, 7 So. 3d at 1254 (emphasis omitted). Hymel then discusses ad nauseam the

24

significance of using specific language in the release.14 In contrast, Hymel mentions
settlement amount third among the facts distinguishing it from Breaux and suggests
that settlement amount has little, if any, relevance when the release specifically
discharges the claim at issue.15
This interpretation is further supported by Hebert v. Avondale Industries, Inc.,
No. 13-0518 (La. App. 4 Cir. 5/1/13), an unpublished opinion from the Louisiana
Fourth Circuit.16 Like Hymel, Hebert held that the plaintiff’s settlement stemming
from his asbestosis lawsuit released his future claim for mesothelioma, even though
the plaintiff did not develop mesothelioma until nearly ten years after executing the
release. The majority opinion reasoned:
[T]he settlement specifically covers both mesothelioma and cancer; Mr.
Hebert had an asbestos related disease at the time he signed the
settlement (asbestosis). He has the potential to recover additional sums
See id. at 1257 (“Where a settlement and release refer expressly to the claim sought to be
released by the party seeking to enforce the settlement, that alone is sufficient to shift the burden to
the party seeking to oppose [its] enforcement . . . to prove that there was no meeting of the minds or
that there was fraud or ill practices.”); id. at 1253 (“The plaintiff has cited no cases in which a court
has invalidated a settlement where the future claim arose out of the original alleged dereliction of duty
and was specifically mentioned in the release and the plaintiff was represented by counsel.”); id.
at 1256 (“In the instant case, the written agreement expressly includes mesothelioma. Therefore, .
. . the burden shifts to the [plaintiff] to show that the parties did not intend to settle the mesothelioma
claim.”); id. at 1256 (“The fact that mesothelioma was specifically mentioned in the release now
before this court distinguishes it from the release [considered by the Louisiana Supreme Court] in
Brown, a distinction which the Brown court indicated was determinative . . . .”); id. at 1255-56
(“Personal injury claims would be impossible to settle were this Court to hold that, as a matter of law,
every new post settlement symptom would give rise to a new claim regardless of the express
language of the settlement to the contrary.”) (emphasis added).
15 See id. at 1254 (“Therefore, he is not in a position to argue that he traded away his whole claim
for mesothelioma for $15,000.00, although it would not have made any difference had he done
so as long as the record shows that he did so, as it does.”); id at 1256 (“A compromise may not be
rescinded for lesion, i.e., a compromise may not be rescinded because it is later determined that the
bargain struck was a poor one. . . . Therefore, the implication in plaintiff’s argument that the
$15,000.00 settlement for what eventuated into mesothelioma was not legally sufficient is not
persuasive.”); id. at 1253 (“When the words of a contract are clear and explicit and lead to no absurd
consequences, no further interpretation may be made in search of the parties’ intent. . . . . It is not
the province of the courts to relieve a party of a bad bargain, no matter how harsh.”)
(emphasis added).
16 A copy of the opinion can be found in the record at Rec. Doc. 161-4 at 18-27.
14

25

from other defendants in the present suit. Mr. Hebert entered into the
agreement willingly and with the advice of counsel. Thus, we find that
the claims now asserted . . . are waived . . . .
Id. at 5 (paragraph break omitted). Conspicuously absent from this analysis is any
reference to the settlement amount. In fact, the Hebert majority deemed the
settlement amount of $1,500.00—which it conceded was a “low number”—to be
“immaterial” to its decision. Id. at 3 & n.1.
Similar to the releases in both Hymel and Hebert, the Champion Release, Met
Life Release, Amchem Release, Chesterton Release, and A.P. Green Release
specifically released future claims for mesothelioma or cancer or both. Also, Savoie
had an asbestos related disease when he signed the releases, was represented by
counsel when he signed the releases, and has the potential to recover additional sums
from other defendants in the present suit. Given these circumstances, it seems highly
unlikely that the settlement amounts, whatever they may be, would qualify as
substantiating evidence of mistaken intent. In any event, if Plaintiffs believe the
settlement amount would make a difference to the outcome, the burden is now on
them to show what those amounts were. See supra discussion re: Plaintiffs’ fourth
argument. This is particularly so given that the Plaintiffs—Savoie’s wife and
children—are in a better position than Avondale to know what amounts were in the
releases Savoie signed.
Plaintiff’s seventh and final argument is that Savoie never intended to settle
his future mesothelioma claim. Plaintiffs cite deposition testimony from Savoie’s wife
who states that she and her husband never intended to give up any rights relating to

26

mesothelioma, that she had never heard of mesothelioma until her husband was
diagnosed with that disease in 2014, that no one explained the releases to them, that
the attorneys who represented them in the Borden case did not have authority to act
on their behalf regarding mesothelioma, etc., etc. Under the circumstances, this
evidence is not enough to avoid summary judgment. See Hymel, 7 So. 3d at 1257
(“Where a settlement and release refer expressly to the claim sought to be released
by the party seeking to enforce the settlement, that alone is sufficient to shift the
burden to the party seeking to oppose the enforcement of the settlement and release
to prove that there was no meeting of the minds or that there was fraud or ill
practices. It is not sufficient to raise the issue to merely make the self-serving
allegation that there was no meeting of the minds. A party represented by counsel
may not defeat a written settlement and release that is unambiguous on its face by
merely alleging that he did not understand it. Otherwise, no settlement would be
enforceable without more litigation which defeats the whole public policy favoring
settlements. Signatures on documents are not mere ornaments. . . . There is little
incentive to settle if a party to the settlement agreement may later seek to void it
based merely on his self-serving statements, without more, and in the absence of any
evidence of fraud or ill practices, that he misunderstood what he signed or that he did
not intend to sign what he signed.”). Plaintiffs’ seventh argument fails.
CONCLUSION
There is no genuine dispute as to a material fact that Savoie released his
mesothelioma claim in the Champion Release, Met Life Release, Amchem Release,

27

Chesterton Release, and A.P Green Release. However, the B & W Release,
Combustion Engineering Release, and the Garlock Release did not release Savoie’s
mesothelioma claim.
Avondale is only entitled to a virile share credit if it can prove at trial that an
entity released by the Champion, Met Life, Amchem,17 Chesterton, or A.P. Green
Releases is liable for Savoie’s mesothelioma. See note 3 and accompanying text, supra.
Accordingly, Avondale’s motion requests that all of the entities released by the
settlements be placed on the jury verdict form. The Court will determine which
entities will be on the verdict form after hearing the evidence at trial. If, for example,
Avondale presents no evidence that a particular releasee is liable, the Court will not
put that entity on the verdict form.
For these reasons,
IT IS ORDERED that Avondale’s Renewed Motion for Partial Summary
Judgment to Establish the Settlements of Certain Non-Parties (Rec. Doc. 280) is
GRANTED IN PART and DENIED IN PART.
New Orleans, Louisiana, this 10th day of June, 2019.

________________________________
United States District Judge

Although Shook & Fletcher is listed as one of the releasees in the Amchem Release, Savoie did not
release his mesothelioma claim against that entity. See Part B.3 of the Discussion, supra. Under no
circumstances, then, can Avondale receive a virile-share credit for Shook & Fletcher.
17

28